NCT03221309View on ClinicalTrials.gov

Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

Active, not recruitingOBSERVATIONAL
Enrollment

198

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

January 22, 2021

Study Completion Date

January 31, 2026

Conditions
HCVBuprenorphinePreP
Interventions
OTHER

Evaluate model of care for HCV-infected adults with on-going opioid misuse

Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated

Trial Locations (2)

20002

HIPS, Washington D.C.

21223

University of Maryland Drug Treatment Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER